# HPW Skill - Medical Nomenclature Guidelines

## 1. Gene and Chromosome Nomenclature

### 1.1 HGVS-Recommended Nomenclature (Human Genome Variation Society)

**Gene Names:**
- Use *italics* for gene symbols (e.g., *BCR-ABL1*, *FLT3*, *NPM1*)
- Use upright/roman text for protein products (e.g., BCR-ABL1 protein, FLT3-ITD)
- Gene symbols should be in ALL CAPS for autosomal genes (e.g., *DNMT3A*)
- Use mixed case for X-linked genes (e.g., *GATA1*, *XIST*)

**Variant Nomenclature:**
- Use HGVS nomenclature for all sequence variants
- Prefix with "c." for coding DNA variants (e.g., c.1794T>G)
- Use "p." prefix for protein changes (e.g., p.VAL617PHE)
- Use "g." for genomic coordinates (e.g., g.12345678G>A)
- Fusion genes: *BCR-ABL1* (not BCR/ABL or bcr-abl1)

**Correct Examples:**
- *BCR-ABL1* fusion gene
- *NPM1* mutation (NPM1 WT = wild-type)
- *FLT3*-internal tandem duplication (FLT3-ITD)
- *TP53* loss-of-function variant
- Complex karyotype with del(5q), -7, and i(17q)

**Incorrect Examples:**
- BCR-ABL fusion (missing hyphen)
- NPM1 mutation (not italicized)
- FLT3 internal tandem duplication (not hyphenated)
- p53 (should be *TP53* for gene)

### 1.2 Cytogenetic Nomenclature (ISCN 2016/2024)

**Structural Abnormalities:**
- del = deletion (e.g., del(5q))
- inv = inversion (e.g., inv(16)(p13.1q22))
- t = translocation (e.g., t(9;22)(q34;q11))
- ins = insertion
- add = additional material of unknown origin
- i = isochromosome (e.g., i(17q))
- der = derivative chromosome

**Numerical Abnormalities:**
- - = monosomy (e.g., -7)
- + = trisomy (e.g., +8)
- cp = complex karyotype (≥3 abnormalities)

**Fusion Genes from Translocations:**
- t(9;22)(q34;q11) → *BCR-ABL1*
- t(8;21)(q22;q22) → *RUNX1-RUNX1T1*
- t(15;17)(q22;q12) → *PML-RARA*
- inv(16)(p13.1q22) → *CBFB-MYH11*

---

## 2. WHO vs ICC Classification

### 2.1 WHO Classification 2022 (5th Edition)

**Key Features:**
- Myeloid neoplasms and acute leukemias
- Integrated approach: morphology, immunophenotype, genetics
- Defined genetic entities as primary classification criterion

**AML Classification:**
- AML with defining genetic abnormalities
- AML with myelodysplasia-related changes
- Therapy-related AML
- AML not otherwise specified

**Key Genetic Entities:**
- AML with t(8;21)(q22;q22); *RUNX1-RUNX1T1*
- AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); *CBFB-MYH11*
- APL with t(15;17)(q22;q12); *PML-RARA*
- AML with t(9;11)(p21.3;q23.3); *MLLT3-KMT2A*
- AML with *NPM1* mutation
- AML with *CEBPA* bZIP mutation

### 2.2 ICC Classification 2022 (International Consensus Classification)

**Key Features:**
- Separates myeloid and lymphoid neoplasms
- More explicit genetic criteria
- New entities and refined categories

**Differences from WHO:**
1. **Terminology:** "myeloid neoplasms" vs "myeloproliferative neoplasms"
2. **MDS Classification:** Different risk stratification
3. **AML Definition:** Lower blast threshold for some entities
4. **New Entities:** More genetically-defined categories

**Side-by-Side Comparison:**

| Feature | WHO 2022 | ICC 2022 |
|---------|----------|----------|
| AML blast threshold | ≥20% | ≥20% (or specific genetic abnormality) |
| MDS-EB | 2 subcategories | 2 subcategories (different thresholds) |
| *NPM1*-mutated AML | Separate entity | Separate entity |
| *TP53*-mutated AML | Separate entity | Separate entity with MDS/AML |
| APL | PML-RARA required | PML-RARA required |

### 2.3 Diagnostic Algorithm Template

**WHO 2022 Diagnostic Criteria:**
1. Identify recurrent genetic abnormalities
2. Apply blast count (≥20% for AML)
3. Assess for myelodysplasia-related features
4. Consider therapy-related setting
5. Classify as "AML, [specific genetic abnormality]"

**ICC 2022 Diagnostic Criteria:**
1. Confirm genetic abnormality first
2. Determine cell lineage (myeloid/lymphoid/biphenotypic)
3. Assess blast percentage
4. Apply risk stratification
5. Classify with explicit genetic criteria

---

## 3. ELN Recommendations

### 3.1 ELN 2022 AML Recommendations

**Risk Stratification (by genetics):**

**Favorable Risk:**
- t(8;21)(q22;q22); *RUNX1-RUNX1T1*
- inv(16)(p13.1q22) or t(16;16)(p13.1;q22); *CBFB-MYH11*
- *NPM1* mutation without FLT3-ITD or with FLT3-ITD low allelic ratio
- *CEBPA* bZIP mutation (double allele)

**Intermediate Risk:**
- *NPM1* mutation with FLT3-ITD high allelic ratio
- Wild-type *NPM1* without FLT3-ITD or with FLT3-ITD low allelic ratio
- t(9;11)(p21.3;q23.3); *MLLT3-KMT2A*
- Other cytogenetic abnormalities not classified

**Adverse Risk:**
- t(6;9)(p23;q34.1); *DEK-NUP214*
- t(v;11q23.3); *KMT2A* rearranged
- t(9;22)(q34;q11); *BCR-ABL1*
- Complex karyotype (≥3 abnormalities)
- Monosomy 5/del(5q)
- *TP53* mutation/abnormality

### 3.2 ELN 2025 CML Recommendations

**Response Definitions:**

**Optimal Response:**
- BCR-ABL1 ≤10% at 3 months
- BCR-ABL1 ≤1% at 6 months
- BCR-ABL1 ≤0.1% (MR2) at 12 months
- BCR-ABL1 ≤0.01% (MR3) by 18 months

**Warning:**
- BCR-ABL1 >10% at 3 months
- BCR-ABL1 >1% at 6 months
- BCR-ABL1 >0.1% at 12 months

**Failure:**
- BCR-ABL1 >10% at 6 months
- BCR-ABL1 >1% at 12 months
- Loss of CHR, CCyR, or MMR
- *BCR-ABL1* kinase domain mutation

---

## 4. NIH GVHD Diagnosis and Grading

### 4.1 Acute GVHD Staging

**Skin:**
- Stage 1: Maculopapular rash <25% BSA
- Stage 2: Maculopapular rash 25-50% BSA
- Stage 3: Maculopapular rash >50% BSA
- Stage 4: Generalized erythroderma + bullae

**Liver (Bilirubin):**
- Stage 1: 2-3 mg/dL
- Stage 2: 3-6 mg/dL
- Stage 3: 6-15 mg/dL
- Stage 4: >15 mg/dL

**Gut:**
- Stage 1: 500 mL diarrhea/day
- Stage 2: 500-1000 mL/day
- Stage 3: >1000 mL/day
- Stage 4: Grade 3 + severe abdominal pain

### 4.2 Chronic GVHD Severity

**Mild (1):**
- 1-2 organs involved
- No significant functional impairment

**Moderate (2):**
- 1-3 organs involved
- Mild-moderate functional impact

**Severe (3):**
- 3+ organs involved
- Significant functional impairment

### 4.3 NIH Diagnostic Criteria for Chronic GVHD

**Definitive Features (Requires Biopsy):**
- Lichen planus-like features (skin)
- Oral mucosa changes
- Liver biopsy with bile duct damage
- Lung biopsy with BOOP/bronchiolitis obliterans

**Characteristic Features:**
- Skin: Poikiloderma, sclerotic features
- Mouth: Xerostomia, ulcers
- Eyes: Keratoconjunctivitis sicca
- Genital: Lichen planus features
- Lungs: OB on PFT

---

## 5. Reference Standards

### 5.1 Primary References

1. **WHO Classification 2022:** Blood. 2022;140(11):1345-1374. doi:10.1182/blood.2022015850
2. **ICC Classification 2022:** Blood Adv. 2022;6(18):5128-5148. doi:10.1182/bloodadvances.2022016867
3. **ELN AML 2022:** Leukemia. 2022;36(7):1703-1719. doi:10.1038/s41375-022-01613-1
4. **ELN CML 2025:** Leukemia. 2025;39(3):xxx-xxx. doi:10.1038/s41375-025-02664-w
5. **HGVS Nomenclature 2024:** https://hgvs-nomenclature.org
6. **NIH GVHD Consensus:** Biol Blood Marrow Transplant. 2005;11(12):945-956

### 5.2 Nomenclature Resources

- **HGVS:** https://varnomen.hgvs.org
- **ISCN:** https://iscn.cog-repository.org
- **HGNC Gene Symbols:** https://www.genenames.org
- **LOINC:** https://loinc.org (for standardized nomenclature)

---

## 6. HPW Implementation Guidelines

### 6.1 Template Usage

When generating manuscripts, apply nomenclature rules based on:
1. **Genetics section:** HGVS + ISCN nomenclature
2. **Diagnosis section:** WHO vs ICC comparison
3. **AML/CML context:** ELN recommendations
4. **Transplant context:** NIH GVHD criteria

### 6.2 Quality Checks

- [ ] Gene symbols italicized
- [ ] HGVS variant nomenclature correct
- [ ] ISCN cytogenetic notation correct
- [ ] Fusion genes properly formatted (*BCR-ABL1*)
- [ ] Risk stratification uses ELN criteria
- [ ] GVHD staging uses NIH criteria

### 6.3 Example Text

**Correct:**
"Patient presented with AML with *NPM1* mutation and FLT3-ITD (allelic ratio 0.45). Cytogenetic analysis revealed a complex karyotype: 46,XX,del(5q),-7,i(17q)[12]/46,XX[8]. According to ELN 2022 criteria, this patient was classified as adverse risk."

**Incorrect:**
"Patient had AML with NPM1 mutation and FLT3 ITD. Cytogenetics showed 5q deletion, monosomy 7, and 17q isochromosome. This was adverse risk per ELN 2022."


---

# HGVS 2024 Updates (Addendum)

## Key Changes from 2016 to 2024

### 1. Somatic Variant Nomenclature

**2024 Recommendation:**
- Separate notation for somatic vs germline variants
- Include Variant Allele Frequency (VAF) when available
- Reference COSMIC database IDs where applicable

**Format:**
```
c.1794T>G;VAF=0.35        # With allelic fraction
COSM12345                  # COSMIC database ID
```

### 2. Copy Number Variations (CNVs)

**Updated Standards:**
- dupl(...) for duplications
- del(...) for deletions
- "x3" suffix for amplifications (e.g., 17q11.2q12x3)

### 3. Fusion Genes

**Standardized Format:**
| Old | 2024 Standard |
|-----|---------------|
| BCR/ABL | *BCR-ABL1* |
| PML/RARA | *PML-RARA* |
| RUNX1/RUNX1T1 | *RUNX1-RUNX1T1* |

### 4. Splicing Variants

**Enhanced Notation:**
- Standardized intronic position numbering
- c.IVS3+5G>A (splice donor/acceptor)
- c.123-2A>G (splice acceptor)

### 5. Reference Sequences

**Required for 2024 Compliance:**
- NM_ prefix for RefSeq mRNA
- NG_ prefix for RefSeq genomic
- LRG_ for Locus Reference Genomic

---

## Implementation Checklist

### Before Manuscript Submission

- [ ] Verify all gene symbols italicized (*BCR-ABL1*, *NPM1*)
- [ ] Check HGVS notation accuracy
- [ ] Confirm cytogenetic notation (ISCN 2024)
- [ ] Include VAF for somatic variants
- [ ] Reference COSMIC IDs for known mutations
- [ ] Specify transcript variants where relevant

### Automated Validation

Use `HPW_Nomenclature_Checker.py` to validate:
```bash
python -c "
from HPW_Nomenclature_Checker import NomenclatureChecker
checker = NomenclatureChecker()
issues = checker.check_all(manuscript_text)
print(checker.generate_report(manuscript_text))
"
```

---

## References

1. HGVS Nomenclature 2024. https://varnomen.hgvs.org
2. COSMIC Database: https://cancer.sanger.ac.uk/cosmic
3. ClinVar: https://www.ncbi.nlm.nih.gov/clinvar
4. ISCN 2024: https://iscn.cog-repository.org
